Annual report pursuant to Section 13 and 15(d)

Quarterly Financial Information (unaudited) (Parenthetical) (Details)

v3.6.0.2
Quarterly Financial Information (unaudited) (Parenthetical) (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2015
Dec. 31, 2015
Error Corrections And Prior Period Adjustments Restatement [Line Items]    
Gain on sale of business   $ 3,505
Novartis [Member]    
Error Corrections And Prior Period Adjustments Restatement [Line Items]    
Upfront payment received $ 37,000  
Novo Nordisk [Member]    
Error Corrections And Prior Period Adjustments Restatement [Line Items]    
Upfront payment received 5,000  
Pfizer [Member]    
Error Corrections And Prior Period Adjustments Restatement [Line Items]    
Upfront payment received 3,800  
Manufacturing Facility in Berkeley, California [Member] | Other Income (Expense), Net [Member]    
Error Corrections And Prior Period Adjustments Restatement [Line Items]    
Gain on sale of business $ 3,500